Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2021

View Archived Issues

LY-487379 shows synergistic effect on low-dose L-DOPA in a marmoset model

SB-0107 shows antiparkinsonian activity in animal models

Researchers establish N. gonorrhoeae upper reproductive tract infection model

Perampanel ameliorates development of alpha-syn pathology in models of PD

Japan Tobacco describes new PDHK2 inhibitors

Kallyope presents new free fatty acid FFA1 receptor agonists

Servier discovers nuclear factor erythroid 2-related factor 2 activators

NLRP3 inflammasome inhibitors patented by Cadila Healthcare

Potent inhibitor of sAC shows potential as nonhormonal contraceptive

Ventus outlines NLRP3 inhibitor program

Second Genome collaborates with VCU to generate biomarker for NASH with advanced fibrosis

Discovery of novel EP3 receptor antagonists

Chimeric spike mRNA-LNP vaccines show cross-protection against Sarbecovirus strains in vivo

Improved method of oligonucleotide synthesis using a novel P(V) platform

Avicanna's novel cannabinoid formulation shows promising preclinical results for epilepsy

Neddylation inhibition identified as a means of treating malignant rhabdoid tumors

Boan reports preclinical research data on CEA/CD3 bispecific antibody BA-1202

Infection derails healing after brain injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.